CLSD logo

CLSD
Clearside Biomedical Inc

5,132
Mkt Cap
$4.32M
Volume
224,055.00
52W High
$17.10
52W Low
$0.31
PE Ratio
-0.19
CLSD Fundamentals
Price
$0.95
Prev Close
$0.8251
Open
$0.627
50D MA
$3.40
Beta
0.53
Avg. Volume
650,737.42
EPS (Annual)
-$6.98
P/B
-0.09
Rev/Employee
$52,000.00
Loading...
Loading...
News
all
press releases
CLSD Stock Plummets After Company Files For Bankruptcy Protection
The biopharmaceutical company is seeking authorization to pursue an auction and sale process.
Stocktwits·10d ago
News Placeholder
More News
News Placeholder
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of -70.15% and -23.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -4.86% and -18.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -5.26% and +15.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·24d ago
News Placeholder
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -11.76% and +35.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·28d ago
News Placeholder
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of +50.00% and +87.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of -14.29% and -76.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Zacks·6mo ago
News Placeholder
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Zacks·7mo ago
News Placeholder
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks·7mo ago

Latest CLSD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.